Lisdexamfetamine Dimesylate Capsule
Product Images NDC 64850-554

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 64850-554). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Elite Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
This text appears to show data related to SKAMP Deportment scores with LS Mean (SE) values for placebo and lisdexamfetamine Dimesylate at different time points post-dose. The values provided seem to represent scores at various time intervals.*
FDA Label Image

Figure 5 (Figure 5)

FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
The text indicates LS Mean (SE) PERMP Total Scores measured at different time points (0, 2, 4, and 8 hours post-dose) for both the Placebo and Lisdexamfetamine Dimesylate groups. The data suggests a comparison of the effects of the two treatments on PERMP Total Scores over time.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
This is not-readable.*
FDA Label Image

Figure 8 (Figure 8)

FDA Label Image

Lisdex Caps 10mg (Lisdex Caps 10mg Bottle Label)

Lisdex Caps 10mg (Lisdex Caps 10mg Bottle Label)
This text seems to be a medication label for capsules containing Lisdexamfetamine. Each capsule contains Lisdexamfetamine dimesylate 10 mg. The manufacturer is Elite Laboratories, Inc. The capsules should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The directions advise keeping the medication in a light-resistant container with a child-resistant closure. Each bottle contains 100 capsules. Pharmacist is advised to dispense an accompanying Medication Guide with each patient.*
FDA Label Image

Lisdex Caps 20mg (Lisdex Caps 20mg Bottle Label)

Lisdex Caps 20mg (Lisdex Caps 20mg Bottle Label)
The provided text seems to be a package insert for a medication called Lisdexamfetamine. Each capsule contains Lisdexamfetamine dimesylate 20 mg, manufactured by Elite Laboratories, Inc. It is recommended to store the medication at a temperature between 20° to 25°C (68° to 77°F). The expiration date of the medication is stated as 04/24. Pharmacists are advised to dispense the medication with a medication guide to each patient and ensure it is in child-resistant packaging. The medication is contained in 100 capsules per bottle.*
FDA Label Image

Lisdex Caps 30mg (Lisdex Caps 30mg Bottle Label)

Lisdex Caps 30mg (Lisdex Caps 30mg Bottle Label)
This text provides important information about a medication called Lisdexamfetamine, specifically the dosage, manufacturer (Elite Laboratories, Inc.), and storage instructions. The medication comes in capsule form, with each capsule containing 30 mg of Lisdexamfetamine dimesylate. The storage temperature ranges from 20°C to 25°C (68°F to 77°F) with excursions permitted up to 15° to 30°C (59°F to 86°F). It also mentions the need for a child-resistant closure and includes a medication guide for patients.*
FDA Label Image

Lisdex Caps 40mg (Lisdex Caps 40mg Bottle Label)

Lisdex Caps 40mg (Lisdex Caps 40mg Bottle Label)
This text appears to be information regarding the dosage instructions and storage of a medication called Lisdexamfetamine. The text includes details about the dosage, manufacturer (Elite Laboratories, Inc.), composition, storage conditions (20°C to 25°C), and packaging (100 capsules with a child-resistant closure). The medication guide needs to be dispensed to each patient along with the medication. The information also includes the National Drug Code (NDC) for this particular medication (64850-553-01).*
FDA Label Image

Lisdex Caps 50mg (Lisdex Caps 50mg Bottle Label)

Lisdex Caps 50mg (Lisdex Caps 50mg Bottle Label)
This text provides information about a medication called Lisdexamfetamine, in the form of capsules containing 50 mg of Lisdexamfetamine dimesylate. The manufacturer is Elite Laboratories, Inc. It is recommended to store the medication at a temperature between 20° to 25°C (68° to 77°F), with excursions permitted to 15° to 30°C (59° to 86°F). The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. The package insert includes a medication guide for each patient.*
FDA Label Image

Lisdex Caps 60mg (Lisdex Caps 60mg Bottle Label)

Lisdex Caps 60mg (Lisdex Caps 60mg Bottle Label)
This text provides information about a medication containing Lisdexamfetamine dimesylate in capsules, each capsule containing 60 mg of the active ingredient. It also includes instructions for storage and dispensing by a pharmacist. The medication is manufactured by Elite Laboratories, Inc. and should be stored at a temperature between 20° to 25°C (68° to 77°F). Additionally, it mentions the NDC number for identification.*
FDA Label Image

Lisdex Caps 70mg (Lisdex Caps 70mg Bottle Label)

Lisdex Caps 70mg (Lisdex Caps 70mg Bottle Label)
This text appears to be a section from a medication package insert. It provides information on a capsule containing Lisdexamfetamine dimesylate 70 mg, manufactured by Elite Laboratories, Inc. The storage conditions are specified as 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The medication should be kept in a tight, light-resistant container with a child-resistant closure. The text includes details on the dosage and expiry date, as well as instructions for pharmacists to dispense the accompanying Medication Guide to each patient. This information is important for safe administration and storage of the medication.*
FDA Label Image

Chemical Structure (Vyvanse 01)

FDA Label Image

Figure 1 (Vyvanse 02)

FDA Label Image

Figure 2 (Vyvanse 03)

Figure 2 (Vyvanse 03)
This text provides information on the change due to PK Fold Change and 90% Confidence Interval for the drugs Guanfacine, Venlafaxine, and Omeprazole. It includes details such as Cmax and Auc for each drug, with a graph showing changes relative to a reference point.*
FDA Label Image

Figure 3 (Vyvanse 04)

Figure 3 (Vyvanse 04)
This description provides information on the PK (pharmacokinetic) fold change and 90% confidence interval for the drug Guanfacine when interacting with various drug substrates classified under different cytochrome P450 (CYP) enzymes such as CYP1A2, CYP2D6, CYP2C19, and CYP3A. The data includes parameters like Cmax (maximum concentration) and AUC (area under the curve) for these substrates. The chart visually represents the fold change relative to the reference drug.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.